



BARDA's Role in Incentivizing Medical Countermeasure Research and Development

Julio Barrera-Oro, PhD
Project Officer, Burn Medical Countermeasures
Biomedical Advanced Research and
Development Authority (BARDA)

2019 CBRN Defense Conference & Exhibition Wilmington, DE

July 23, 2019















ASPR Priorities for Building Readiness for 21st Century Threats











The BARDA Model

BARDA develops and makes available medical countermeasures (MCMs) by forming unique public-private partnerships to drive innovation off the bench to the patient to save lives.



Our Government Partners













NATIONAL CANCER INSTITUTE
Technology Transfer Center
































































Our Industry Partners



45 FDA Approvals, Licensures, and Clearances





Project BioShield

A COMMITMENT

27 Products supported



15 Products added to the Strategic National Stockpile



Products taken to FDA approval/licensure/clearance













NEUPOGE

(FILGRASTIM)



BioThrax **
Anthrax Vaccine Adsorbed












STRATEGIC NATIONAL STOCKPILE USE ONLY





21st Century: An Increasingly Complex

& Dangerous World





CBRN Priority Investment Areas


Stockpile at least one countermeasure for all threats that have a material threat determination

Develop innovative rapid response capabilities to address unknown threats

Repurpose products to treat injuries from radiological, nuclear and chemical threats

Invest in new antibacterial agents, vaccines and rapid point of care diagnostics

Deliver countermeasures against chemical and viral hemorrhagic fever threats







Biopharmaceutical accelerator: Model partnership to support innovation and early R&D

FUNDERS













ALLIANCE PARTNER







OTHER PARTNERS & ACCELERATORS























BARDA Division of Research, Innovation, and Ventures (DRIVe)

DRIVe Mission: Transforming Health Security

Accelerate the research, development, and availability of transformative countermeasures to protect Americans from natural and intentional health security threats.





DRIVe-Ready

CAPTURE

Set targets & research agenda Coordinate with "deep thinkers" across USG, academia, industry, and other stakeholders.

SOLUTION MAPPING

Establish Integrated Solutions for Intelligent Acceleration



ACCELERATE

Investors: BARDA, DoD

DRIVe-Launch

(1-18 Months)

Investors: BARDA, MCIP



STRATEGIC SUSTAINMENT

Corporate Venture Capital Model Investment in Products

PHEMCE 2.0 Industry DoD



BARDA Has Had a Successful Decade



Formed strong partnerships with over 250 industry partners



Supported 45
FDA licensure/
approvals across
40 different
medical
countermeasures



Supported 27 different projects under Project BioShield,15 products added to the Strategic National Stockpile, 10 FDA licensures



Significantly
expanded
domestic vaccine
production
capacity: 60 M
doses to 600 M
antigen doses for
influenza



Accelerated antibacterial product development to address critical vulnerabilities



How to Contact BARDA









medicalcountermeasures.

gov

Portal to BARDA: Register to request a TechWatch meeting!

www.fbo.gov/

("FedBizOpps")

Official announcements and info for all government contract solicitations

www.phe.gov/BARDA

Program description, information, news, announcements

www.drive.hhs.gov

DRIVe questions



www.usajobs.gov

Join the team!







